Drug reference

Hepatitis B immunoglobulin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1379, 1380

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Prophylaxis against hepatitis B infection ▶BY INTRAMUSCULAR INJECTION ▶Adult: 500 units, dose to be administered as soon as possible after exposure; ideally within 12–48 hours, but no later than 7 days after exposure Prophylaxis against hepatitis B infection, after exposure to hepatitis B virus-contaminated material ▶BY INTRAVENOUS INFUSION ▶Adult: Dose to be administered as soon as possible after exposure, but no later than 72 hours (consult product literature) Prevention of hepatitis B in haemodialysed patients ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature) Prophylaxis against re-infection of transplanted liver ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature) Prevention of hepatitis B re-infection more than 6 months after liver transplantation in stable HBV-DNA negative patients ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight up to 75 kg): 500 units once weekly, increased if necessary up to 1000 units once weekly, dose to be started 2–3 weeks after last dose of intravenous hepatitis B immunoglobulin ▶Adult (body-weight 75 kg and above): 1000 units once weekly, dose to be started 2–3 weeks after last dose of intravenous hepatitis B immunoglobulin

PDF page 1379

Cautions

IgA deﬁciency. interference with live virus vaccines

PDF page 1379

Prescribing And Dispensing Information

Vials containing 200 units or 500 units (for intramuscular injection), available from selected Public Health England and NHS laboratories (except for Transplant Centres), also available from BPL. l HANDLING AND STORAGE Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

PDF pages 1379, 1380

Safety

Interactions

→Appendix 1: immunoglobulins

PDF page 1379

Side Effects

▶Uncommon Abdominal pain upper. headache ▶Rare or very rare Cardiac discomfort. fatigue. hypersensitivity. hypertension. hypotension. muscle spasms. nasopharyngitis. oropharyngeal pain. palpitations. skin reactions

PDF page 1379

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Hepatitis B immunoglobulin (Non-proprietary) Hepatitis B immunoglobulin human 200 unit Hepatitis B immunoglobulin human 200unit solution for injection vials | 1 vial P £200.00 Hepatitis B immunoglobulin human 500 unit Hepatitis B immunoglobulin human 500unit solution for injection vials | 1 vial P £400.00 ▶Zutectra (Biotest (UK) Ltd) Zutectra 500units/1ml solution for injection pre-filled syringes | 5 syringe P £1,500.00 Solution for infusion ▶Hepatect CP (Biotest (UK) Ltd) Hepatitis B immunoglobulin human 50 unit per 1 ml Hepatect CP 100units/2ml solution for infusion vials | 1 vial P £55.00 Hepatect CP 2000units/40ml solution for infusion vials | 1 vial P Vaccines £1,100.00 Hepatect CP 500units/10ml solution for infusion vials | 1 vial P £275.00 Hepatect CP 5000units/100ml solution for infusion vials | 1 vial P £2,750.00 ▶Omri-Hep-B (Imported (Israel)) Hepatitis B immunoglobulin human 50 unit per 1 ml Omri-Hep-B 5000units/100ml solution for infusion vials | 1 vial P s

PDF page 1380

Dose text by age group

Adult

500 units, dose to be administered as soon as

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult

Dose to be administered as soon as possible after

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult (body-weight up to 75 kg)

500 units once weekly,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult (body-weight 75 kg and above)

1000 units once

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Hepatitis B immunoglobulin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1379, 1380

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 1379

Cautions

IgA deﬁciency. interference with live virus vaccines

PDF page 1379

Prescribing And Dispensing Information

PDF pages 1379, 1380

Safety

Interactions

→Appendix 1: immunoglobulins

PDF page 1379

Side Effects

PDF page 1379

Dose and formulations

Medicinal Forms

PDF page 1380

Dose text by age group

Adult

500 units, dose to be administered as soon as

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult

Dose to be administered as soon as possible after

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult (body-weight up to 75 kg)

500 units once weekly,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Adult (body-weight 75 kg and above)

1000 units once

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1379

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.